vs
Side-by-side financial comparison of KEY TRONIC CORP (KTCC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $96.3M, roughly 1.8× KEY TRONIC CORP). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -8.9%, a 10.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -15.4%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -17.8%).
Key Tronic Corporation is a technology company founded in 1969 by Lewis G. Zirkle. Its core products initially included keyboards, mice and other input devices. Key Tronic currently specializes in PCBA and full product assembly. The company is among the ten largest contract manufacturers providing electronic manufacturing services in the US. The company offers full product design or assembly of a wide variety of household goods and electronic products such as keyboards, printed circuit board ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
KTCC vs PCRX — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $96.3M | $177.4M |
| Net Profit | $-8.6M | $2.9M |
| Gross Margin | 0.6% | — |
| Operating Margin | -10.7% | 3.9% |
| Net Margin | -8.9% | 1.6% |
| Revenue YoY | -15.4% | 5.0% |
| Net Profit YoY | -74.4% | — |
| EPS (diluted) | $-0.79 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $96.3M | $196.9M | ||
| Q3 25 | $98.8M | $179.5M | ||
| Q2 25 | $110.5M | $181.1M | ||
| Q1 25 | $112.0M | $168.9M | ||
| Q4 24 | $113.9M | $187.3M | ||
| Q3 24 | $131.6M | $168.6M | ||
| Q2 24 | $126.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-2.3M | $5.4M | ||
| Q2 25 | $-3.9M | $-4.8M | ||
| Q1 25 | $-604.0K | $4.8M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $1.1M | $-143.5M | ||
| Q2 24 | $-2.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 79.5% | ||
| Q3 25 | 8.4% | 80.9% | ||
| Q2 25 | 6.2% | 77.4% | ||
| Q1 25 | 7.7% | 79.7% | ||
| Q4 24 | 6.8% | 78.7% | ||
| Q3 24 | 10.1% | 76.9% | ||
| Q2 24 | 7.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -10.7% | 1.2% | ||
| Q3 25 | -0.6% | 3.5% | ||
| Q2 25 | -2.1% | 4.7% | ||
| Q1 25 | -0.4% | 1.2% | ||
| Q4 24 | -1.0% | 13.2% | ||
| Q3 24 | 3.4% | -82.8% | ||
| Q2 24 | 0.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -8.9% | — | ||
| Q3 25 | -2.3% | 3.0% | ||
| Q2 25 | -3.6% | -2.7% | ||
| Q1 25 | -0.5% | 2.8% | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | 0.9% | -85.1% | ||
| Q2 24 | -1.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.79 | $0.05 | ||
| Q3 25 | $-0.21 | $0.12 | ||
| Q2 25 | $-0.35 | $-0.11 | ||
| Q1 25 | $-0.06 | $0.10 | ||
| Q4 24 | $-0.46 | $0.38 | ||
| Q3 24 | $0.10 | $-3.11 | ||
| Q2 24 | $-0.18 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $788.0K | $144.3M |
| Total DebtLower is stronger | $97.7M | — |
| Stockholders' EquityBook value | $106.2M | $653.9M |
| Total Assets | $325.3M | $1.2B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $788.0K | $238.4M | ||
| Q3 25 | $1.1M | $246.3M | ||
| Q2 25 | $1.4M | $445.9M | ||
| Q1 25 | $2.5M | $493.6M | ||
| Q4 24 | $4.2M | $484.6M | ||
| Q3 24 | $6.6M | $453.8M | ||
| Q2 24 | $4.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $97.7M | $372.2M | ||
| Q3 25 | $100.8M | $376.7M | ||
| Q2 25 | $105.2M | $580.5M | ||
| Q1 25 | $113.6M | $583.4M | ||
| Q4 24 | $111.1M | $585.3M | ||
| Q3 24 | $112.7M | — | ||
| Q2 24 | $119.5M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $106.2M | $693.1M | ||
| Q3 25 | $114.8M | $727.2M | ||
| Q2 25 | $117.1M | $757.8M | ||
| Q1 25 | $119.6M | $798.5M | ||
| Q4 24 | $119.5M | $778.3M | ||
| Q3 24 | $124.3M | $749.6M | ||
| Q2 24 | $124.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $325.3M | $1.3B | ||
| Q3 25 | $324.6M | $1.3B | ||
| Q2 25 | $315.9M | $1.5B | ||
| Q1 25 | $328.6M | $1.6B | ||
| Q4 24 | $327.8M | $1.6B | ||
| Q3 24 | $355.9M | $1.5B | ||
| Q2 24 | $355.3M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.92× | 0.54× | ||
| Q3 25 | 0.88× | 0.52× | ||
| Q2 25 | 0.90× | 0.77× | ||
| Q1 25 | 0.95× | 0.73× | ||
| Q4 24 | 0.93× | 0.75× | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.4M | — |
| Free Cash FlowOCF − Capex | $3.1M | — |
| FCF MarginFCF / Revenue | 3.2% | — |
| Capex IntensityCapex / Revenue | 3.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $11.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $6.4M | $43.7M | ||
| Q3 25 | $7.6M | $60.8M | ||
| Q2 25 | $8.8M | $12.0M | ||
| Q1 25 | $-1.4M | $35.5M | ||
| Q4 24 | $1.6M | $33.1M | ||
| Q3 24 | $9.9M | $53.9M | ||
| Q2 24 | $7.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.1M | $43.5M | ||
| Q3 25 | $4.4M | $57.0M | ||
| Q2 25 | $7.7M | $9.3M | ||
| Q1 25 | $-3.6M | $26.9M | ||
| Q4 24 | $1.1M | $31.0M | ||
| Q3 24 | $9.6M | $49.8M | ||
| Q2 24 | $7.1M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.2% | 22.1% | ||
| Q3 25 | 4.5% | 31.7% | ||
| Q2 25 | 7.0% | 5.1% | ||
| Q1 25 | -3.2% | 15.9% | ||
| Q4 24 | 1.0% | 16.6% | ||
| Q3 24 | 7.3% | 29.6% | ||
| Q2 24 | 5.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.1% | ||
| Q3 25 | 3.2% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 2.0% | 5.1% | ||
| Q4 24 | 0.4% | 1.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.85× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KTCC
| Transferred Over Time | $91.3M | 95% |
| Transferred At Point In Time | $5.0M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
